VCU Receives NIH Grant for Heart Failure Trial

Researchers at Virginia Commonwealth University will test an anti-inflammatory drug in a phase 2 heart failure study.

Updated on Oct. 30, 2026 in Heart Disease

A close-up view of glass laboratory beakers and medical vials on a sterile white table, representing scientific research. — Virginia Commonwealth University received a $3.8 million NIH grant to conduct a five-year phase 2 clinical trial testing anti-inflammatory heart failure treatment. AI Illustration. Upload story photo >

Live Poll

Do you believe federal funding for experimental clinical trials is a good use of tax dollars?

The National Institutes of Health awarded Virginia Commonwealth University a $3.8 million grant to conduct a five-year phase 2 clinical trial. The study will evaluate whether an anti-inflammatory medication can improve recovery outcomes for patients hospitalized with acute heart failure.

Why it matters

Researchers are investigating whether blocking inflammatory pathways via interleukin-1 can specifically help patients recover from acute heart failure. This study seeks to build upon mixed results from previous pilot research regarding the drug's efficacy in cardiac settings.

The study targets 80 participants and follows a 2025 trial of 102 patients that found no significant clinical benefit. Researchers will measure efficacy through echocardiograms, blood pressure monitoring, and exercise capacity tests after hospital discharge.

The players

Virginia Commonwealth University

This public research university in Richmond serves as the grant recipient and primary site for clinical patient recruitment.

National Institutes of Health

This federal agency is the primary medical research branch of the U.S. Department of Health and Human Services.

University of Virginia

This institution acts as a collaborator to analyze blood samples for determining the study treatment effects.

The details

Virginia Commonwealth University will collaborate with the University of Virginia to analyze blood samples for markers of inflammatory activity. Patients in the trial will be randomized to receive either the treatment or a placebo to isolate the effects of the medication on heart recovery.

A pilot study involving 30 patients was conducted in 2016.
A 2025 study of 102 patients showed no significant clinical benefit.
The $3.8 million NIH grant award was announced on October 26, 2026.
Recruitment for the trial is expected to begin in early 2027.

The Big Picture

This study is part of the National Institutes of Health's clinical research funding initiatives that evaluate new applications for existing medications. It follows a pattern of investigating inflammation-based therapies to address chronic and acute cardiac conditions.

Patients currently managing heart failure can monitor this trial for potential future treatment options if findings indicate the therapy is effective. The study results will determine if larger clinical trials are justified to expand therapeutic availability.

The takeaway

This trial aims to clarify whether targeting specific inflammatory proteins can aid recovery for heart failure patients. If successful, the study could shift how physicians approach anti-inflammatory treatments during post-hospitalization care.